These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12950426)

  • 1. Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects.
    Rordorf C; Kellett N; Mair S; Ford M; Milosavljev S; Branson J; Scott G
    Aliment Pharmacol Ther; 2003 Sep; 18(5):533-41. PubMed ID: 12950426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: An integrated study.
    Atherton C; Jones J; McKaig B; Bebb J; Cunliffe R; Burdsall J; Brough J; Stevenson D; Bonner J; Rordorf C; Scott G; Branson J; Hawkey CJ
    Clin Gastroenterol Hepatol; 2004 Feb; 2(2):113-20. PubMed ID: 15017615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole.
    Hawkey CJ; Ell C; Simon B; Albert J; Keuchel M; McAlindon M; Fortun P; Schumann S; Bolten W; Shonde A; Hugot JL; Yu V; Arulmani U; Krammer G; Rebuli R; Toth E
    Clin Gastroenterol Hepatol; 2008 May; 6(5):536-44. PubMed ID: 18242145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years.
    Goldstein JL; Aisenberg J; Lanza F; Schwartz H; Sands GH; Berger MF; Pan S
    Clin Ther; 2006 Mar; 28(3):340-51. PubMed ID: 16750449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics.
    Hawkey CJ; Farkouh M; Gitton X; Ehrsam E; Huels J; Richardson P
    Aliment Pharmacol Ther; 2004 Jul; 20(1):51-63. PubMed ID: 15225171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo.
    Sheldon E; Beaulieu A; Paster Z; Dutta D; Yu S; Sloan VS
    Clin Ther; 2005 Jan; 27(1):64-77. PubMed ID: 15763607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, one-week study comparing effects of a novel COX-2 inhibitor and naproxen on the gastric mucosa.
    Moberly JB; Harris SI; Riff DS; Dale JC; Breese T; McLaughlin P; Lawson J; Wan Y; Xu J; Truitt KE
    Dig Dis Sci; 2007 Feb; 52(2):442-50. PubMed ID: 17216336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo.
    Harris SI; Kuss M; Hubbard RC; Goldstein JL
    Clin Ther; 2001 Sep; 23(9):1422-8. PubMed ID: 11589257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of lumiracoxib in the treatment of primary dysmenorrhoea.
    Bitner M; Kattenhorn J; Hatfield C; Gao J; Kellstein D
    Int J Clin Pract; 2004 Apr; 58(4):340-5. PubMed ID: 15161117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, crossover comparative endoscopy study on the gastroduodenal tolerability of a highly specific cyclooxygenase-2 inhibitor, flosulide, and naproxen.
    Bjarnason I; Macpherson A; Rotman H; Schupp J; Hayllar J
    Scand J Gastroenterol; 1997 Feb; 32(2):126-30. PubMed ID: 9051872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen.
    Lanza FL; Rack MF; Simon TJ; Quan H; Bolognese JA; Hoover ME; Wilson FR; Harper SE
    Aliment Pharmacol Ther; 1999 Jun; 13(6):761-7. PubMed ID: 10383505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis.
    Hawkey CC; Svoboda P; Fiedorowicz-Fabrycy IF; Nasonov EL; Pikhlak EG; Cousin M; Gitton X; Hoexter G
    J Rheumatol; 2004 Sep; 31(9):1804-10. PubMed ID: 15338504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
    Simon LS; Weaver AL; Graham DY; Kivitz AJ; Lipsky PE; Hubbard RC; Isakson PC; Verburg KM; Yu SS; Zhao WW; Geis GS
    JAMA; 1999 Nov; 282(20):1921-8. PubMed ID: 10580457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
    Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Matchaba P; Gimona A; Hawkey CJ;
    Lancet; 2004 Aug 21-27; 364(9435):665-74. PubMed ID: 15325831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis.
    Hawkey CJ; Gitton X; Hoexter G; Richard D; Weinstein WM
    Clin Gastroenterol Hepatol; 2006 Jan; 4(1):57-66. PubMed ID: 16431306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lumiracoxib: pharmacokinetic and pharmacodynamic profile when coadministered with fluconazole in healthy subjects.
    Scott G; Yih L; Yeh CM; Milosavljev S; Laurent A; Rordorf C
    J Clin Pharmacol; 2004 Feb; 44(2):193-9. PubMed ID: 14747429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lumiracoxib (Prexige): a new selective COX-2 inhibitor.
    Mysler E
    Int J Clin Pract; 2004 Jun; 58(6):606-11. PubMed ID: 15311562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The post-operative analgesic efficacy and tolerability of lumiracoxib compared with placebo and naproxen after total knee or hip arthroplasty.
    Chan VW; Clark AJ; Davis JC; Wolf RS; Kellstein D; Jayawardene S
    Acta Anaesthesiol Scand; 2005 Nov; 49(10):1491-500. PubMed ID: 16223396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis.
    Kivitz AJ; Nayiager S; Schimansky T; Gimona A; Thurston HJ; Hawkey C
    Aliment Pharmacol Ther; 2004 Jun; 19(11):1189-98. PubMed ID: 15153172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production.
    Wight NJ; Gottesdiener K; Garlick NM; Atherton CT; Novak S; Gertz BJ; Calder NA; Cote J; Wong P; Dallob A; Hawkey CJ
    Gastroenterology; 2001 Mar; 120(4):867-73. PubMed ID: 11231941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.